Cannabinoids Reduce Inflammation but Inhibit Lymphocyte Recovery in Murine Models of Bone Marrow Transplantation.
Animals
Bone Marrow Transplantation
/ adverse effects
Cannabidiol
/ pharmacology
Disease Models, Animal
Dronabinol
/ pharmacology
Female
Graft vs Host Disease
/ drug therapy
Inflammation
/ drug therapy
Lymphocyte Activation
/ drug effects
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Treatment Outcome
D9 tetrahydrocannabinol
bone marrow transplantation
cannabidiol
cannabinoid receptor 2
cannabis
graft versus host disease
hematopoiesis
immune
lymphocyte
phytocannabinoids
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Feb 2019
04 Feb 2019
Historique:
received:
19
12
2018
revised:
30
01
2019
accepted:
31
01
2019
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
25
6
2019
Statut:
epublish
Résumé
Cannabinoids, the biologically active constituents of Cannabis, have potent neuronal and immunological effects. However, the basic and medical research dedicated to medical cannabis and cannabinoids is limited. The influence of these treatments on hematologic reconstitution and on the development of graft versus host disease (GVHD) after bone marrow transplantation (BMT) is largely unknown. In this research, we compared the influence of D9 tetrahydrocannabinol (THC) and cannabidiol (CBD) on lymphocyte activation in vitro and in murine BMT models. Our in vitro results demonstrate that these treatments decrease activated lymphocyte proliferation and affect cytokine secretion. We also discovered that CBD and THC utilize different receptors to mediate these effects. In vivo, in a syngeneic transplantation model, we demonstrate that all treatments inhibit lymphocyte reconstitution and show the inhibitory role of the cannabinoid receptor type 2 (CB2) on lymphocyte recovery. Although pure cannabinoids exhibited a superior effect in vitro, in an allogeneic (C57BL/6 to BALB/c) BMT mouse model, THC-high and CBD-high cannabis extracts treatment reduced the severity of GVHD and improved survival significantly better than the pure cannabinoids. Our results highlights the complexity of using cannabinoids-based treatments and the need for additional comparative scientific results.
Identifiants
pubmed: 30720730
pii: ijms20030668
doi: 10.3390/ijms20030668
pmc: PMC6387311
pii:
doi:
Substances chimiques
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Israeli ministry of Agriculture and Rural development
ID : 56-18-0001
Références
Trends Immunol. 2005 Mar;26(3):136-40
pubmed: 15745855
Nat Rev Immunol. 2005 May;5(5):400-11
pubmed: 15864274
Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):696-701
pubmed: 16407142
Biochim Biophys Acta. 2007 Aug;1771(8):1014-30
pubmed: 17418635
Nature. 2008 May 1;453(7191):65-71
pubmed: 18362915
Eur J Pharmacol. 2008 Oct 24;595(1-3):1-6
pubmed: 18778813
Nat Immunol. 2009 Apr;10(4):403-11
pubmed: 19252491
J Exp Med. 2009 Sep 28;206(10):2079-89
pubmed: 19737866
Immunobiology. 2010 Aug;215(8):588-97
pubmed: 20153077
Nat Rev Cancer. 2010 Mar;10(3):213-21
pubmed: 20168320
Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):25-34
pubmed: 20377992
Leukemia. 2010 Dec;24(12):1993-2002
pubmed: 20882043
J Pharmacol Exp Ther. 2011 Sep;338(3):819-28
pubmed: 21673072
Br J Pharmacol. 2011 Aug;163(7):1344-64
pubmed: 21749363
Transfusion. 2011 Nov;51 Suppl 4:65S-71S
pubmed: 22074629
PLoS One. 2011;6(12):e28159
pubmed: 22163000
Curr Opin Hematol. 2012 Jul;19(4):324-35
pubmed: 22517587
Nat Rev Immunol. 2012 May 11;12(6):443-58
pubmed: 22576252
Prog Lipid Res. 2013 Oct;52(4):633-50
pubmed: 24076098
Biol Blood Marrow Transplant. 2014 Jun;20(6):752-9
pubmed: 24565991
Cell Cycle. 2014;13(24):3938-47
pubmed: 25427281
Bioorg Med Chem. 2015 Apr 1;23(7):1377-85
pubmed: 25703248
Egypt J Immunol. 2014;21(2):33-47
pubmed: 25812351
Stem Cells. 2015 Jul;33(7):2256-67
pubmed: 25850816
Biol Blood Marrow Transplant. 2015 Oct;21(10):1770-5
pubmed: 26033282
Mediators Inflamm. 2015;2015:538670
pubmed: 26101464
Life Sci. 2015 Sep 1;136:87-93
pubmed: 26187180
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:157-66
pubmed: 26216862
Chem Biol Drug Des. 2016 Jan;87(1):143-53
pubmed: 26259697
Front Plant Sci. 2016 Feb 04;7:19
pubmed: 26870049
Biofactors. 2016 Nov 12;42(6):581-590
pubmed: 27151562
Adv Pharmacol. 2017;80:291-328
pubmed: 28826538
Exp Hematol. 2018 Jan;57:30-41.e1
pubmed: 29030083
Front Immunol. 2017 Nov 10;8:1487
pubmed: 29176975
Eur J Biochem. 1995 Aug 15;232(1):54-61
pubmed: 7556170
Stem Cells. 1994 Sep;12(5):456-65
pubmed: 7804122
Crit Rev Neurobiol. 1997;11(2-3):143-66
pubmed: 9209828
J Pharmacol Exp Ther. 1998 Apr;285(1):285-92
pubmed: 9536023
Immunol Today. 1998 Aug;19(8):373-81
pubmed: 9709506